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ABSTRACT 
 
The dorsal striatum is a key node for many neurobiological processes such as motor activity, 
cognitive functions, and affective processes. The proper functioning of striatal neurons relies 
critically on metabotropic receptors. Specifically, the main adenosine and endocannabinoid 
receptors present in the striatum, i.e., adenosine A2A receptor (A2AR) and cannabinoid CB1 
receptor (CB1R), are of pivotal importance in the control of neuronal excitability. Facilitatory 
and inhibitory functional interactions between striatal A2AR and CB1R have been reported, 
and evidence supports that this cross-talk may rely, at least in part, on the formation of A2AR-
CB1R heteromeric complexes. However, the specific location and properties of these 
heteromers have remained largely unknown. Here, by using techniques that allowed a precise 
visualization of the heteromers in situ in combination with sophisticated genetically-modified 
animal models, together with biochemical and pharmacological approaches, we provide a 
high resolution expression map and a detailed functional characterization of A2AR-CB1R 
heteromers in the dorsal striatum. Specifically, our data unveil that the A2AR-CB1R heteromer 
(i) is essentially absent from corticostriatal projections and striatonigral neurons, and, instead, 
is largely present in striatopallidal neurons, (ii) displays a striking G protein-coupled signaling 
profile, where co-stimulation of both receptors leads to strongly reduced downstream 
signaling, and (iii) undergoes an unprecedented dysfunction in Huntington’s disease, an 
archetypal disease that affects striatal neurons. Altogether, our findings may open a new 
conceptual framework to understand the role of coordinated adenosine-endocannabinoid 
signaling in the indirect striatal pathway, which may be relevant in motor function and 
neurodegenerative diseases. 
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INTRODUCTION 
 
The dorsal striatum is a key node for many neurobiological processes such as motor activity, 
cognitive functions, and affective processes. The vast majority (~95%) of neurons within the 
striatum are GABAergic medium spiny neurons (MSNs), which receive glutamatergic inputs 
primarily from the cortex. MSNs differ in their neurochemical composition and form two 
major efferent pathways, the direct (striatonigral) pathway and the indirect (striatopallidal) 
pathway (Kreitzer, 2009). The proper functioning of MSNs relies critically on metabotropic 
receptor signaling. Many neurotransmitters and neuromodulators such as dopamine, 
glutamate, endocannabinoids and adenosine control MSN activity and plasticity by engaging 
their cognate G protein-coupled receptors (GPCRs) (Lovinger, 2010; Girault, 2012). 
Specifically, the main endocannabinoid and adenosine receptors present in MSNs, i.e., 
cannabinoid type 1 receptor (CB1R) and adenosine subtype 2A receptor (A2AR), are of pivotal 
importance in the control of neuronal excitability. CB1R is one of the most abundant GPCRs 
in MSNs (Glass et al, 2000; Castillo et al, 2012). In particular, CB1R is highly expressed in 
the terminals of both striatonigral and striatopallidal MSNs, where it mediates 
endocannabinoid-dependent inhibition of GABA release, thus decreasing motor activity 
(Katona and Freund, 2008; Castillo et al, 2012). CB1R is also expressed in glutamatergic 
terminals projecting from the cortex onto the striatum, where it controls MSN function by 
blunting glutamatergic output and mediating the so-called endocannabinoid-dependent long-
term depression (Kreitzer, 2009; Castillo et al, 2012). A2AR is also very abundant in the 
striatum (Schiffmann and Vanderhaeghen, 1993; Schiffmann et al, 2007). Presynaptically, a 
significant fraction of the corticostriatal projections that expresses CB1R also contains A2AR. 
These A2AR molecules are mostly located on corticostriatal terminals that form synaptic 
contacts with striatonigral MSNs (Quiroz et al, 2009; Ferreira et al, 2015). Blockade of 
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presynaptic A2AR counteracts glutamate release and motor output evoked by cortical 
stimulation (Quiroz et al, 2009; Orru et al, 2011; Tebano et al, 2012). Postsynaptically, A2AR 
is selectively located on striatopallidal MSNs, which co-express dopamine D2 receptor (D2R) 
(Schiffmann et al, 2007; Azdad et al, 2009; Tebano et al, 2012). Blockade of postsynaptic 
A2AR mediates the motor-activating effects of A2AR antagonists, consistent with an 
inactivation of the indirect pathway (Orru et al, 2011; Tebano et al, 2012). 
 The high expression of A2AR and CB1R in the striatum, together with the key 
involvement of both receptors in the control of motor and goal-directed behaviors, have led to 
a large number of studies on the interactions between them (Ferre et al, 2010; Tebano et al, 
2012). Understanding these interactions is of special relevance not only physiologically but 
also pharmacologically as these receptors are targets of widely consumed psychoactive 
substances such as caffeine (an A2AR antagonist) and Δ9-tetrahydrocannabinol (a CB1R 
agonist). Both facilitatory and inhibitory functional interactions between striatal A2AR and 
CB1R have been demonstrated (Ferre et al, 2010; Tebano et al, 2012; Justinova et al, 2014). 
The precise molecular mechanisms underlying the cross-talk between these receptors is yet to 
be fully understood, but some evidence supports that they may rely, at least in part, on the 
formation of A2AR-CB1R heteromeric complexes (Carriba et al, 2007; Ferre et al, 2010; 
Tebano et al, 2012; Chiodi et al, 2016). Despite more than ten years of research on GPCR 
heteromers, there continues to be a major gap in our understanding of where exactly 
heteromers are expressed as well as linking them to precise signal transduction pathways and 
biological functions. In the case of the A2AR-CB1R heteromer, factors to consider include (i) 
the additional partners with which A2AR and CB1R could interact differently at presynaptic 
sites (e.g., A1R) (Ciruela et al, 2006) or postsynaptic sites (e.g., D2R and mGluR5) (Navarro et 
al, 2008; Azdad et al, 2009; Cabello et al, 2009; Bonaventura et al, 2014; Bonaventura et al, 
2015), (ii) the convergence of adenosine and endocannabinoid actions on various intracellular 
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signaling pathways (Ferre et al, 2010; Tebano et al, 2012), and (iii) the intricate network of 
molecular processes controlling adenosine and endocannabinoid release (Kreitzer and 
Malenka, 2005; Lerner et al, 2010). 
 Previous studies on the A2AR-CB1R heteromer have relied essentially on energy 
transfer-based assays in cells ectopically expressing A2AR and CB1R, as well as co-
immunolocalization and co-immunoprecipitation experiments (Carriba et al, 2007; Navarro et 
al, 2008; Bonaventura et al, 2014). These approaches, although widely exploited and certainly 
valuable, possess limitations of spatial resolution (co-immunolocalization), molecular 
specificity (co-immunoprecipitation) and biological interpretation (energy transfer using 
protein overexpression) to characterize GPCR heteromers. Hence, here we made use of 
techniques to allow a precise visualization of the heteromers in situ in combination with 
sophisticated genetically-modified mouse models, together with biochemical and 
pharmacological approaches, to cogently characterize the anatomy and signaling profile of the 
A2AR-CB1R heteromer in the dorsal striatum. 
 
MATERIALS AND METHODS 
 
The experimental procedures used in this study are extensively described in Supplementary 
Materials and Methods. That section provides precise details on animal models [genetic 
mouse models to study the location of the A2AR-CB1R heteromer, as well as mouse models of 
Huntington’s disease (HD)], human post-mortem brain samples (see also Supplementary 
Table S1), recombinant adeno-associated viral vectors, HIV TAT peptides designed to disrupt 
the A2AR-CB1R heteromer, cell culture and transfection procedures, in situ proximity ligation 
assays (PLA), fluorescence complementation assays, dynamic mass redistribution (DMR) 
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label-free assays, cAMP and Ca2+ concentration assays, Western blotting assays, 
immunomicroscopy procedures, and statistical analyses (see also Supplementary Table S2). 
 
RESULTS 
 
A2AR-CB1R heteromers are located on GABAergic neurons rather than glutamatergic 
projections in the mouse dorsal striatum 
To clarify the precise location of A2AR-CB1R heteromers in the dorsal striatum we conducted 
PLA experiments. The PLA assay is a powerful and straightforward technique to detect 
protein-protein interactions in general, and GPCR oligomers in particular, and to localize 
these complexes in situ with cell sub-population selectivity, thus allowing an unbiased 
demonstration and quantification of protein complexes in unmodified cells and tissues (Taura 
et al, 2015). Importantly, PLA permits assessing close proximity between proteins within an 
oligomer with high resolution (< 40 nm). As PLA relies on the amplification of a small signal, 
its main limitation is antibody specificity/background noise, which we minimize by adapting 
refined technical protocols as well as employing multiple genetic mouse models and controls 
(Taura et al, 2015). Here, we first used conditional mutant mice bearing a genetic deletion of 
CB1R in forebrain GABAergic neurons (CB1Rfloxed/floxed;Dlx5/6-Cre/+ mice; herein referred to as 
GABA-CB1R-/- mice) or dorsal telencephalic glutamatergic neurons (CB1Rfloxed/floxed;Nex-Cre/+ 
mice; herein referred to as Glu-CB1R-/- mice) (Monory et al, 2006). Striatal A2AR-CB1R 
heteromers were evident almost exclusively as dots in the vicinity of cell nuclei, and showed a 
remarkable reduction in GABA-CB1R-/- mice (Figure 1a, c). In contrast, no significant 
differences were observed between Glu-CB1R-/- mice and CB1Rfloxed/floxed;+/+ controls (Figure 
1a, c) when data were expressed either as a percentage of cells containing one or more dots 
relative to total cell nuclei (Figure 1c) or as a total number of dots relative to total cell nuclei 
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(CB1Rfloxed/floxed mice: 2.23 ± 0.16; Glu-CB1R-/- mice: 2.40 ± 0.20; n = 3 animals of each 
genotype). In addition, Glu-CB1R-/- mice did not show any significant reduction in the 
percentage of A2AR-CB1R heteromer-positive cells relative to total cell nuclei in their motor 
cortices (CB1Rfloxed/floxed mice: 70.3 ± 2.3; Glu-CB1R-/- mice: 71.4 ± 3.0; n = 3 animals of each 
genotype). Likewise, the expression levels of A2AR-CB1R heteromers displayed by GABA-
CB1R-/- mice were not decreased further when the CB1R gene was simultaneously ablated in 
glutamatergic neurons (CB1Rfloxed/floxed;Dlx5/6-Cre;Nex-Cre mice; herein referred to as GABA-Glu-
CB1R-/- mice) (Bellocchio et al, 2010) (Figure 1a, c). Control experiments conducted in the 
absence of one of the two primary antibodies, as well as in full CB1R-/- mice (Marsicano et al, 
2002) and full A2AR-/- mice (Ledent et al, 1997), provided strong support to the specificity of 
the PLA analyses performed (Supplementary Figure S1a-c). Of note, a different anti-CB1R 
primary antibody provided a similar A2AR-CB1R heteromer detection (Supplementary Figure 
S1d). Moreover, the specificity of the primary antibodies used was also demonstrated by 
immunocytofluorescence studies conducted in HEK-293T cells transfected or not with 
cDNAs encoding human A2AR or human CB1R (Supplementary Figure S1e). 
To unequivocally ascribe A2AR-CB1R heteromers to GABAergic neurons we made 
use of a Cre-mediated, lineage-specific CB1R re-expression/rescue strategy in a CB1R-null 
background (herein referred to as Stop-CB1R mice) (Ruehle et al, 2013; de Salas-Quiroga et 
al, 2015). The selective rescue of CB1R expression in forebrain GABAergic neurons (herein 
referred to as GABA-CB1R-RS mice) was achieved by expressing Cre under the regulatory 
elements of the Dlx5/6 gene (de Salas-Quiroga et al, 2015). In parallel, we rescued CB1R 
expression selectively in dorsal telencephalic glutamatergic neurons (herein referred to as 
Glu-CB1R-RS mice) by using a Nex-Cre mouse line (Ruehle et al, 2013). As a control, an 
EIIa-Cre-mediated, global CB1R expression-rescue in a CB1R-null background was 
conducted (herein referred to as CB1R-RS mice) (Ruehle et al, 2013). Remarkably, the 
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expression levels of A2AR-CB1R heteromers were notably restored in GABA-CB1R-RS mice 
(Figure 1b, c). In contrast, no significant rescue of the heteromer was observed in Glu-CB1R-
RS animals when data were expressed either as a percentage of cells containing one or more 
dots relative to total cell nuclei (Figure 1c) or as a total number of dots relative to total cell 
nuclei (Stop-CB1R mice: 0.24 ± 0.01; Glu-CB1R-RS mice: 0.28 ± 0.04; n = 3 animals of each 
genotype). 
Taken together, these data strongly support that, in the mouse dorsal striatum, A2AR-
CB1R heteromers are located on GABAergic neurons rather than glutamatergic projections. 
 
A2AR-CB1R heteromers are located on indirect-pathway MSNs in the mouse dorsal 
striatum 
The vast majority (~95%) of neurons within the striatum are MSNs (Kreitzer, 2009). These 
neurons differ in their neurochemical composition and form two major efferent pathways. The 
direct pathway consists of MSNs expressing markers such as dopamine D1 receptor (D1R) and 
substance P. It mainly projects to the substantia nigra pars reticulata and the internal segment 
of the globus pallidus. The indirect pathway is composed of MSNs expressing markers such 
as D2R and enkephalin. It mainly projects to the external segment of the globus pallidus, 
which, in turn, projects to the subthalamic nucleus (Kreitzer, 2009). CB1R is located on both 
direct-pathway and indirect-pathway MSNs, while A2AR resides essentially on indirect-
pathway MSNs (Schiffmann et al, 2007; Kreitzer, 2009; Castillo et al, 2012). As a 
consequence, A2AR-CB1R heteromers would conceivably be located on indirect-pathway 
MSNs. To substantiate this possibility, we first used conditional mutant mice bearing a 
genetic deletion of CB1R in D1R-expressing neurons (CB1Rfloxed/floxed;Drd1a-Cre/+ mice; herein 
referred to as D1R-CB1R-/- mice) (Monory et al, 2007). No differences were observed in the 
expression of A2AR-CB1R heteromers, as assessed by PLA analyses, between D1R-CB1R-/- 
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mice and control mice (Supplementary Figure S2a), thus confirming that the heteromer is not 
located on direct-pathway MSNs. CB1R is essentially a presynaptic receptor that, in MSNs, 
resides ,mainly on terminals and collaterals (Katona et al, 2008; Kreitzer, 2009; Castillo et al, 
2012). Hence, we also studied the projection sites of MSNs in CB1Rfloxed/floxed mice. 
Specifically, we injected stereotactically these CB1Rfloxed/floxed mice with a recombinant adeno-
associated viral vector encoding Cre (or EGFP to gain visualization of neuronal projections) 
into the dorsal striatum (or the motor cortex as control). Cre expression was driven by a 
CaMKIIα promoter, so it was confined to MSNs (injections into the striatum) or principal 
neurons (injections into the cortex) (Chiarlone et al, 2014). Cre-mediated excision of the 
loxP-flanked CB1R gene in dorsal-striatum MSNs of CB1Rfloxed/floxed mice reduced the 
expression of A2AR-CB1R heteromers in the globus pallidus (Supplementary Figure S2b). In 
contrast, inactivation of the CB1R gene in the motor cortices of CB1Rfloxed/floxed mice did not 
affect the expression of A2AR-CB1R heteromers on corticostriatal inputs (Supplementary 
Figure S2c). 
 Collectively, these data show that, in the mouse dorsal striatum, A2AR-CB1R 
heteromers are primarily located on indirect-pathway MSNs. 
 
A2AR-CB1R heteromers expressed in the mouse dorsal striatum are functional 
Previous reports have shown the existence of both facilitatory and inhibitory functional 
interactions between A2AR and CB1R (Ferre et al, 2010; Tebano et al, 2012). To investigate 
the possible role of the A2AR-CB1R heteromer in these interactions we characterized in detail 
heteromer functionality in the dorsal striatum. For this purpose we used C57BL/6N-mouse 
striatal slices and conducted cell signaling experiments on two pathways coupled to A2AR and 
CB1R: extracellular signal-regulated kinase (ERK) and Akt. The CB1R agonist WIN-55,212-2 
or the A2AR agonist CGS21680 increased ERK phosphorylation (activation) in the dorsal 
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striatum, whereas co-incubation with both agonists abrogated ERK phosphorylation, thus 
demonstrating a negative cross-talk between A2AR and CB1R (Figure 2a). In addition, the 
CB1R antagonist SR141716 (rimonabant) or the A2AR antagonist ZM241385 prevented the 
ERK-activating effect of WIN-55,212-2 or CGS21680 (Figure 2a). These data show a cross-
antagonism between the two receptors, a phenomenon not uncommon in heteromers. When 
these cross-pharmacological assays were conducted for Akt phosphorylation (activation), 
similar negative cross-talk and cross-antagonism processes were observed (Figure 2a). 
Collectively, these findings demonstrate the existence of inhibitory interactions between A2AR 
and CB1R in the mouse dorsal striatum. 
 Next, we sought to substantiate that the aforementioned negative cross-talk and cross-
antagonism between A2AR and CB1R rely on A2AR-CB1R heteromers. It is generally believed 
that agonist binding to the extracellular pocket of GPCRs induces local conformational 
changes that increase signaling by opening an intracellular cavity via the movement of 
transmembrane helices (TMs) 5 and 6 for receptor activation, while, conversely, inverse 
agonists decrease the basal, agonist-independent, level of signaling by closing this cavity 
(Shoichet and Kobilka, 2012; Venkatakrishnan et al, 2013). In fact, the reported crystal 
structure of the agonist-bound A2AR, compared to the inactive, antagonist-bound A2AR, shows 
an outward tilt and rotation of the cytoplasmic half of TM6 and a movement of TM5, thus 
resembling the changes associated with the active-state structure of other class A GPCRs (Xu 
et al, 2011). Likewise, the crystal structure of the antagonist-bound CB1R has been recently 
reported, showing a similar opsin-like behavior for this receptor (Hua et al, 2016; Shao et al, 
2016). Our aforementioned observation that A2AR-CB1R heteromers display both negative 
cross-talk and cross-antagonism suggests a negative modulation between both receptors 
through protein-protein interactions involving the TM5/TM6 interface. Hence, to test this 
hypothesis, we studied whether synthetic peptides with the sequence of TM5, TM6 or TM7 
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(as negative control) of CB1R, fused to HIV TAT peptide to allow efficient intracellular 
delivery and plasma membrane insertion (Schwarze et al, 1999; He et al, 2011), were able to 
disrupt A2AR-CB1R heteromerization and the observed bidirectional cross-signaling. This 
approach has been recently used by us and others to disrupt other heteromers (Guitart et al, 
2014; Lee et al, 2014; Viñals et al, 2015). 
We first characterized the TM interference peptides by the bimolecular fluorescence 
complementation technique. In this assay, fluorescence only appears after correct folding of 
two YFP Venus hemiproteins. This occurs when two receptors fused to hemi-YFP Venus 
proteins (cYFP or nYFP) come within proximity to facilitate YFP Venus folding (Figure 2b, 
scheme). Fluorescence was detected in HEK-293T cells transfected with different amounts of 
cDNA encoding CB1R-nYFP and A2AR-cYFP, but not in negative controls in which cells 
were transfected with cDNA encoding CB1R-nYFP and the non-interacting D1R-cYFP 
(Figure 2b). The TM-targeted peptides were subsequently tested. We found that treatment of 
cells expressing CB1R-nYFP and A2AR-cYFP with TM5 or TM6 (but not TM7) peptides 
disrupted the heteromer structure, as revealed by a loss of fluorescence (Figure 2b). We next 
studied the effect of the interference peptides on A2AR and CB1R signaling in mouse striatal 
slices. When the peptides were evaluated in cross-pharmacological assays, we found that 
pretreatment of brain slices with TM5, TM6 or both (but not TM7) peptides disrupted (i) the 
ability of the CB1R agonist WIN-55,212-2 and the CB1R antagonist SR141716 to dampen 
A2AR-evoked actions on ERK and Akt, as well as (ii) the ability of the A2AR agonist 
CGS21680 and the A2AR antagonist ZM241385 to dampen CB1R-evoked actions on these 
two signaling pathways (Figure 2c). Of note, when the TM5 and TM6 peptides were used in 
combination, the increase in ERK and Akt phosphorylation upon receptor co-activation 
tended to be higher compared to TM5-only or TM6-only incubations (Figure 2c), thus 
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conceivably reflecting that the peptide combination is more efficient than each peptide alone 
in disrupting the heteromer. 
Together, these data provide evidence for the importance of the TM5/TM6 interface in 
the A2AR-CB1R heteromer, and support that the negative cross-talk and cross-antagonism that 
occurs between CB1R and A2AR are due to protein-protein interactions and are a specific 
biochemical characteristic of the A2AR-CB1R heteromer. 
 
Functional A2AR-CB1R heteromers are present in wild-type and mutant huntingtin-
expressing striatal neuroblasts 
To evaluate the relevance of the A2AR-CB1R heteromer in a pathological setting we selected 
HD as a model because (i) it is the paradigmatic disease primarily caused by a selective loss 
of MSNs in the dorsal striatum (Walker, 2007), and (ii) changes in the expression and 
function of A2AR and CB1R have been shown to occur in the dorsal striatum of patients and 
animal models of the disease (Glass et al, 2000; Fernandez-Ruiz et al, 2011; Lee and Chern, 
2014). We first characterized the heteromer in conditionally immortalized striatal neuroblasts 
expressing two normal (STHdhQ7) or mutant (STHdhQ111) full-length endogenous huntingtin 
alleles with 7 or 111 glutamine residues, respectively, which represent a widely accepted 
cellular model to investigate huntingtin actions. These cells do not exhibit mutant-huntingtin 
inclusions (Trettel et al, 2000), thus allowing the modeling of changes occurring at early HD 
stages. 
 We readily detected PLA-positive A2AR-CB1R heteromers in both STHdhQ7 and 
STHdhQ111 cells (Figure 3a), indicating that the mere expression of mutant huntingtin does not 
prevent heteromerization of both receptors. To evaluate the functional characteristics of 
A2AR-CB1R heteromers, we first measured the global cellular response using DMR label-free 
assays, which detect changes in light diffraction in the bottom 150 nm of a cell monolayer. In 
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these experiments we had a preference for CP-55,940 over WIN-55,212-2 as the CB1R 
agonist because the former is less hydrophobic than the latter and so conceivably more 
accessible to cultured cells. In fact, dose-response experiments conducted in both STHdhQ7 
and STHdhQ111 cells showed that CP-55,940 impacted the DMR signal more markedly than 
WIN-55,212-2 (Supplementary Figure S3a, b). Both the A2AR agonist CGS21680 and the 
CB1R agonist CP-55,940 induced time-dependent signaling in STHdhQ7 and STHdhQ111 cells 
(Figure 3b). Of note, A2AR and CB1R-evoked signaling was essentially insensitive to pertussis 
toxin (PTX) or cholera toxin (CTX) (Figure 3b), thus indicating that these receptors do not 
significantly couple to Gi or Gs proteins in these cells. This notion was further supported by 
the observation that, in both STHdhQ7 cells (Supplementary Figure S4a) and STHdhQ111 cells 
(Supplementary Figure S4b), neither the A2AR agonist nor the CB1R agonist was able to affect 
basal or forskolin-elevated cAMP concentrations in the absence or presence of PTX or CTX. 
In line with this apparent lack of “classical” A2AR-Gs/olf and CB1R-Gi coupling, the Gq protein 
inhibitor YM-254890 was able to abrogate the A2AR and CB1R-evoked changes in DMR 
(Figure 3c). This non-conventional coupling did appear to be due to heteromer formation as 
experiments conducted with the TM5 and TM6 peptides on STHdhQ7 and STHdhQ111 cells 
showed that the peptide combination, presumably by disrupting the heteromer, turned A2AR 
and CB1R action to their “classical”, “protomeric” Gs/olf and Gi-mediated signaling, 
respectively (Supplementary Figure S4c). This strongly supports that there is no limitation of 
Gs/olf or Gi protein availability in these cells, as previously indicated by others’ work (Araki et 
al, 2006), and that the A2AR-CB1R heteromer couples selectively to Gq. Moreover, and further 
supporting a Gq-dependent signaling for the heteromer, engagement of A2AR or CB1R 
increased intracellular free Ca2+ concentration in both STHdhQ7 and STHdhQ111 cells 
(Supplementary Figure S5). 
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 We next investigated whether the heteromer specific biochemical properties described 
above could influence Gq-driven signaling. Regarding negative cross-talk, the DMR signal 
induced by the A2AR agonist CGS21680 alone or the CB1R agonist CP-55,940 alone was 
attenuated when both agonists were added together to STHdhQ7 or STHdhQ111 cells (Figure 
3d, top panels). Regarding cross-antagonism, the DMR signal induced by the CB1R agonist 
was prevented not only by the CB1R antagonist SR141716 but also by the A2AR antagonist 
ZM241385, and, similarly, the DMR signal induced by the A2AR agonist CGS21680 was also 
prevented by either antagonist (Figure 3d, bottom panels). Of note, the combination of the 
TM5 and TM6 peptides disrupted the cross-antagonism between A2AR and CB1R in STHdhQ7 
and STHdhQ111 cells (Figure 3d, bottom panels). 
 Collectively, these data indicate that coexpression of A2AR and CB1R, likely through 
the formation of A2AR-CB1R heteromers, facilitates Gq rather than Gs or Gi coupling in wild-
type and mutant huntingtin-expressing mouse striatal neuroblasts. 
 
Functional A2AR-CB1R heteromers are expressed in HD mice at early but not advanced 
disease stages 
To study the role of A2AR-CB1R heteromers in HD in vivo we analyzed their expression and 
function in a widely accepted model of HD, heterozygous mutant knock-in HdhQ7/Q111 mice, 
that express in heterozygosity a mutant full-length huntingtin allele with 111 glutamine 
residues, and wild-type HdhQ7/Q7 mice, that express two wild-type full-length huntingtin 
alleles with 7 glutamine residues. At an early stage of the disease (4 months of age), mutant 
HdhQ7/Q111 mice displayed A2AR-CB1R heteromers in the dorsal striatum at similar levels as 
wild-type HdhQ7/Q7 mice (Figure 4a). However, at more advanced stages (6 and 8 months of 
age), the expression of A2AR-CB1R heteromers was almost completely lost in mutant 
HdhQ7/Q111 mice but not wild-type HdhQ7/Q7 mice (Figure 4a). Of note, total striatal A2AR and 
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CB1R expression, as determined by Western blot (Supplementary Figure S6a) and 
immunofluorescence microscopy (Supplementary Figure S6b), was largely preserved in 6 
month-old mutant HdhQ7/Q111 mice compared to age-matched wild-type HdhQ7/Q7 mice. Hence, 
irrespective of the small differences found between the Western blot and immunofluorescence 
data, which can be conceivably due to the intrinsic characteristics of the two techniques, these 
findings suggest that the massive loss of A2AR-CB1R heteromers found in HdhQ7/Q111 mice is 
mostly heteromer-selective and not primarily due to a mere reduction of total A2AR and CB1R 
molecules. In agreement with this notion, and as a further proof of the selective loss, the 
expression of another CB1R heteromer previously reported in indirect-pathway MSNs, 
namely CB1R-D2R (Navarro et al, 2008; Bonaventura et al, 2014), was not reduced in 6 
month-old mutant HdhQ7/Q111 mice compared to their wild-type controls (Supplementary 
Figure S6c). Moreover, a remarkable loss of A2AR-CB1R heteromers was also observed in 
advanced stages of mouse models of HD transgenic for human mutant huntingtin exon 1, 
specifically R6/1 mice (Supplementary Figure S7a) and R6/2 mice (Supplementary Figure 
S7b). Again, the expression of CB1R-D2R heteromers, used as a control, did not decrease in 
advanced-stage R6/1 or R6/2 mice compared to age-matched wild-type animals 
(Supplementary Figure S7c). 
 CB1R is highly abundant in most MSNs (Katona et al, 2008; Castillo et al, 2012), but 
it has been reported that the down-regulation of CB1R mRNA expression in R6 transgenic 
mice is striatum subregion-selective, occurring preferentially in the dorsolateral than the 
dorsomedial striatum (Denovan-Wright and Robertson, 2000; McCaw et al, 2004). Hence we 
analyzed the expression of total A2AR and CB1R immunoreactivity, as well as that of the 
A2AR-CB1R heteromer, in the dorsolateral vs. the dorsomedial striatum of wild-type HdhQ7/Q7 
and mutant HdhQ7/Q111 mice at 6 months of age. We found no significant differences between 
the two dorsal-striatum compartments in total A2AR immunoreactivity in either HdhQ7/Q7 mice 
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(relative values: dorsolateral: 100 ± 5.7; A2AR, dorsomedial: 101.8 ± 5.7; n = 3 animals) or 
HdhQ7/Q111 mice (relative values: dorsolateral: 100 ± 5.2; A2AR, dorsomedial: 114.8 ± 7.8; n = 
3 animals). There was a moderate preference of total CB1R protein expression for the 
dorsolateral striatum in HdhQ7/Q7 mice (relative values: dorsolateral: 100 ± 3.8; dorsomedial: 
83.1 ± 2.5; n = 3 animals; p = 0.032), as well as a non-significant trend in HdhQ7/Q111 mice 
(relative values: dorsolateral: 100 ± 2.9; dorsomedial: 85.8 ± 2.7; n = 3 animals). Regarding 
the A2AR-CB1R heteromer, we found no significant differences between the two dorsal-
striatum compartments in the percentage of heteromer-positive cells relative to total cell 
nuclei in either HdhQ7/Q7 mice (dorsolateral: 45.0 ± 4.9; dorsomedial: 44.0 ± 3.8; n = 3 
animals) or HdhQ7/Q111 mice (dorsolateral: 10.4 ± 2.3; dorsomedial: 7.5 ± 1.4; n = 4 animals). 
Overall, these data show that the A2AR-CB1R heteromer has a rather similar expression 
pattern in the mouse dorsolateral and dorsomedial striatum. 
 To study the function of the A2AR-CB1R heteromer in HD mice we performed cross-
signaling experiments in striatal slices from 6 month-old HdhQ7/Q7 and HdhQ7/Q111 mice. 
Consistently with the aforementioned data on both cell and slice cultures from control 
C57BL/6N mice, dual agonist treatment with WIN-55,212-2 and CGS21680 depressed 
phospho-ERK or phospho-Akt signal compared to single-agonist stimulation in wild-type 
HdhQ7/Q7 mice, thus showing a negative cross-talk (Figure 4b, c). In addition, the action of 
both agonists was blocked when the slices were preincubated with the partner receptor 
antagonists, SR141716 or ZM241385, thus showing cross-antagonism (Figure 4b, c). 
Interestingly, in HdhQ7/Q111 mice this negative cross-talk and cross-antagonism signature was 
not detected (Figure 4d, e), in line with the PLA data showing that the A2AR-CB1R heteromer 
is indeed not expressed in 6 month-old HdhQ7/Q111 mice. Of note, and also in line with the data 
shown above, this loss of cross-signaling did not appear to be simply due to the loss of surface 
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expression of functional receptors, as the extent of single agonist-evoked ERK and Akt 
stimulation was roughly equivalent in both HdhQ7/Q111 and HdhQ7/Q7 mice (Figure 4b-e). 
 Together, these data demonstrate that a selective loss of functional A2AR-CB1R 
heteromers accompanies disease progression in mouse models of HD. 
 
A2AR-CB1R heteromers are lost in the caudate-putamen of high-grade HD patients 
We next investigated whether the aforementioned changes in A2AR-CB1R heteromer 
expression found in HD mouse models are also evident in HD. Thus, we used the PLA 
technique to analyze human caudate-putamen post-mortem samples from control subjects and 
HD patients at different grades. A2AR-CB1R heteromers were readily evident in the caudate-
putamen of control individuals, with a high fraction (~65%) of total cells expressing 
heteromers (Figure 5a, g, and Supplementary Table S1). These complexes were also detected 
at those normal levels in asymptomatic huntingtin gene-mutation carriers (HD grade 0) and 
early symptomatic HD patients (HD grades 1-2) (Figure 5b-d, g, and Supplementary Table 
S1). In contrast, A2AR-CB1R heteromers were strongly reduced in caudate-putamen samples 
from high-grade, advanced HD patients (HD grades 3-4), with only ~10% of total cells 
containing PLA-positive dots (Figure 5e-g, and Supplementary Table S1). PLA labeling was 
quite uniform in the caudate-putamen sections analyzed, and thus no perceptible differences 
in A2AR-CB1R heteromer expression were detected between those two nuclei within each 
subject (Supplementary Figure S8a, b). In addition, the demographic characteristics of the 
samples used indicated that the control, low-grade HD and high-grade HD subject populations 
were rather homogeneous (Supplementary Table S1), thus supporting that the differences 
found in A2AR-CB1R heteromer expression were not due to those confounding factors. Taken 
together, these data support that the human brain expresses A2AR-CB1R heteromers, and 
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suggest that these complexes might serve specific functions that are impaired at late stages of 
HD progression. 
 
DISCUSSION 
 
Despite the progress made towards identifying and understanding GPCR heteromers, their 
promise as precision drug targets has yet to be fully realized due to the lack of detailed 
expression maps and functional profiles. A first important conclusion of our study refers to 
the precise location of the A2AR-CB1R heteromer in the mouse dorsal striatum. The current 
view in the field supports that a major site of A2AR and CB1R colocalization is the 
corticostriatal-neuron terminal, at which the two receptors could physically interact to form 
A2AR-CB1R heteromers (Figure 5h). These presynaptic heteromers have been suggested to 
provide a frame to explain, at least in part, the negative pharmacological interactions between 
A2AR and CB1R that occur in the corticostriatal pathway (Ferre et al, 2010; Tebano et al, 
2012; Ferreira et al, 2015; Chiodi et al, 2016). However, those previous studies on A2AR-
CB1R heteromers, although elegant and carefully conducted, lacked state-of-the-art genetic 
controls and heteromer-detecting techniques. Thus, to evaluate the possible existence of 
A2AR-CB1R heteromers in corticostriatal neurons, we have made use of three potent genetic 
models, namely (i) mice lacking CB1R selectively in cortical glutamatergic neurons, (ii) 
CB1R-deficient mice in which CB1R expression is selectively rescued in cortical 
glutamatergic neurons, and (iii) CB1R-floxed mice in which CB1R is selectively excised in 
corticostriatal neurons. Systematic PLA assays conducted in these mouse models strikingly 
showed that the expression of the A2AR-CB1R heteromer in corticostriatal projections to the 
dorsal striatum is negligible (Figure 1c). This finding supports that the inhibitory cross-talk 
processes between A2AR and CB1R reported to date in corticostriatal terminals do not rely 
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primarily on physical interactions between the two receptors at the plasma membrane, but on 
other potential factors such us an opposite Gs/Gi protein-dependent downstream signaling 
converging on glutamate release at the presynapse, which, in turn, would conceivably lead to 
an opposite modulation of the mGluR5/phospholipase C-β/diacylglycerol lipase-α 
(DAGLα)/2-arachidonoylglycerol (2-AG) retrograde-signaling machinery at the postsynapse 
(Uchigashima et al, 2007; Katona et al, 2008). In any case, this observed absence of 
presynaptic A2AR-CB1R heteromers does certainly not preclude that A2AR and CB1R could 
interact with other partners at corticostriatal terminals to form GPCR complexes, for example 
the A1R-A2AR heteromer (Ciruela et al, 2006; Quiroz et al, 2009). 
 Another widely accepted site at which striatal A2AR-CB1R heteromers are believed to 
reside is the somatodendritic compartment of MSNs, the main target of corticostriatal inputs 
(Carriba et al, 2007; Schiffmann et al, 2007; Ferre et al, 2010) (Figure 5h). Here, by using (i) 
mice lacking CB1R selectively in GABAergic neurons, (ii) CB1R-deficient mice in which 
CB1R expression is selectively rescued in GABAergic neurons, (iii) mice lacking CB1R 
selectively in D1R-expressing MSNs, and (iv) CB1R-floxed mice in which CB1R is selectively 
excised in MSNs, we cogently demonstrated that the A2AR-CB1R heteromer is indeed present 
in indirect-pathway MSNs (Figure 1 and Supplementary Figure S2). It is well established that 
CB1R is largely a presynaptic receptor that is highly abundant in the resident collaterals and 
long-range projections of MSNs (Uchigashima et al, 2007; Katona et al, 2008). Our data 
support that A2AR-CB1R heteromers are not solely expressed in the somatodendritic 
compartment of indirect-pathway MSNs, but, most likely, also at terminals of these neurons 
(Figure 5h). Nonetheless, the higher PLA signal found in GABA-CB1R-/- and GABA-Glu-
CB1R-/-mice compared to full CB1R-/- mice (Figure 1c and Supplementary Figure S1c) 
suggests that, in the dorsal striatum, A2AR-CB1R heteromers may also be located on non-
GABAergic, non-glutamatergic cells/terminals such as cholinergic interneurons, 
 21
dopaminergic projections or astrocytes. We are also aware that understanding the precise role 
of A2AR-CB1R complexes in indirect-pathway MSNs is an extremely complex issue. This 
complexity is due, in part, to the possibility that A2AR and CB1R can interact with other 
receptors in indirect-pathway MSNs. For example, A2AR is highly coexpressed with both D2R 
and mGluR5, which colocalizes with DAGLα at the perisynaptic border of dendritic spines of 
MSNs (Uchigashima et al, 2007; Katona et al, 2008). The activation of mGluR5 by glutamate 
spillover derived from corticostriatal overactivity, which leads to DAGLα-mediated 2-AG 
generation, can be tuned by D2R in MSN dendritic spines (Kreitzer et al, 2005; Yin and 
Lovinger, 2006). In addition, A2AR antagonists potentiate 2-AG release and long-term 
depression in indirect-pathway MSNs (Lerner et al, 2010). Whether these intricate 
interactions between A2AR, D2R and mGluR5 rely, at least in part, on putative A2AR-D2R-
mGluR5 heteromers (Cabello et al, 2009) has still to be defined. To complicate the situation 
further, postsynaptic A2AR and D2R might form other higher-order heteromeric complexes, 
including a proposed A2AR-CB1R-D2R heteromer (Navarro et al, 2010; Bonaventura et al, 
2014). This functional conundrum notwithstanding, the present study provides a cogent 
understanding of the anatomical distribution of the A2AR-CB1R heteromer, or the complexes 
containing the heteromer, in the corticostriatal circuit. 
 Our data also support that the selective coupling to Gq protein, rather than to Gs or Gi 
proteins, is a biochemical hallmark of the A2AR-CB1R heteromer in striatal cells (Figure 5h). 
A G protein switch has in fact been suggested to occur in several GPCR heteromerization 
processes. For example, a change from the archetypical Gs-coupled D1R (either as monomer 
or as D1R-D1R homomers) to non-canonical Gi-coupled D1R-HT3R heteromer has been 
observed (Ferrada et al, 2009). In addition, formation of the CB1R-5-HT2AR heteromer may 
lead to a switch in G protein coupling for 5-HT2AR from Gq to Gi protein (Viñals et al, 2015). 
Thus, it is possible that in a striatopallidal MSN there is a coexistence of A2AR and CB1R (as 
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both monomers and A2AR-A2AR and CB1R-CB1R homomers), which are widely believed to 
couple to Gs/olf and Gi proteins, respectively, together with A2AR-CB1R heteromers, which 
could couple non-canonically to Gq protein. How these processes of GPCR protein-protein 
interaction and subsequent G protein “shuffling” affect corticostriatal circuitry is as yet 
unknown. It is conceivable that the arrangement of the aforementioned heteromers from A2AR 
and CB1R protomers in striatopallidal MSNs, by recruiting activatory Gq proteins, would be a 
way to fuel the indirect pathway and therefore blunt motor activity. However, such a 
functional outcome is difficult to predict as, according to the currently accepted models of 
basal ganglia function, motor activation relies on the simultaneous and coordinated activation 
of the direct and indirect striatal pathways (Nelson and Kreitzer, 2014). In any case, our data 
support the existence of different pools of A2AR and CB1R with different G protein coupling 
in corticostriatal projections, striatopallidal MSNs and striatonigral MSNs, thus providing 
adenosinergic and cannabinergic cross-signaling with an extreme degree of complexity. 
 To study whether the A2AR-CB1R heteromer is affected in a pathological setting we 
selected HD as the archetypal neurodegenerative disease that primarily affects MSNs in a 
selective manner. A significant number of studies have dealt with CB1R expression and 
function in HD. In particular, a down-regulation of CB1R expression has been documented in 
the caudate-putamen of HD patients and the dorsal striatum of some HD animal models, 
which seems to reflect the characteristic damage pattern of MSNs (Glass et al, 2000; 
Fernandez-Ruiz et al, 2011). In addition, we (Blazquez et al, 2011) and others (Mievis et al, 
2011b) have demonstrated a neuroprotective role of CB1R in transgenic mouse models of HD. 
Likewise, administration of the cannabinoid agonist THC to HD mice prevented disease 
progression as assessed by behavioral, neuropathological and molecular markers (Blazquez et 
al, 2011). In sum, it is currently believed that CB1R may be neuroprotective in HD. Regarding 
A2AR, its expression has been shown to decrease in striatopallidal MSNs from the caudate-
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putamen of HD patients and the dorsal striatum of some HD animal models (Glass et al, 
2000; Lee and Chern, 2014). However, the precise role of A2AR in HD progression is not 
obvious yet, as conflicting results have been reported. Thus, administration of the A2AR 
agonist CGS21680 to HD mice prevented neuropathological deficits and improved motor 
alterations, although it had no effect on body weight or lifespan (Chou et al, 2005). Likewise, 
the dual-function compound T1-11, which simultaneously activates A2AR and blocks 
adenosine transport, improved motor coordination deficits, reduced striatal huntingtin 
aggregates and normalized proteasomal activity (Huang et al, 2011). Genetic ablation of 
A2AR in HD mice worsened motor performance, decreased animal survival and reduced 
striatal enkephalin expression (Mievis et al, 2011a), and also reversed working memory 
deficits (Li et al, 2015). However, and in striking contrast, administration of the A2AR 
antagonist SCH58261 exerted beneficial effects in HD mice by attenuating anxiety-like 
responses and sensitivity to excitotoxins, although it had no effect on motor coordination 
(Domenici et al, 2007). Because of these (at least apparently) contradictory data coming from 
various A2AR gain-of-function and loss-of-function approaches, it is conceivable that A2AR 
can mediate different (even opposing) molecular and physiopathological mechanisms 
depending on its cellular location and, hence, its extent of heteromerization. It has been 
proposed that a selective functional impairment of A2AR located on striatopallidal MSNs 
occurs at pre-symptomatic stages of HD, while presynaptic A2AR function is not affected 
(Orru et al, 2011). Of note, CB1R is also lost in MSNs but not in corticostriatal projections 
along HD progression (Chiodi et al, 2012; Chiarlone et al, 2014). This suggests that the 
corticostriatal pool of non-heteromerizing A2AR and CB1R would be the main target of 
adenosinergic and cannabinergic drugs aimed at relieving the symptoms of HD at late stages, 
while the MSN pool of A2AR-CB1R heteromers could be an additional target of those drugs at 
early disease stages. As A2AR-CB1R heteromers are lost in the caudate-putamen of high-grade 
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HD patients, the heteromer’s specific functions would be impaired at advanced stages of HD 
progression. Thus, the fine negative cross-talk between adenosine and endocannabinoids 
would conceivably disappear in advanced HD, and one might speculate that the Gq specific 
signaling would be lost as well at those late disease stages (Figure 5h). The A2AR-CB1R 
heteromer is singular in both its specific localization on indirect-pathway MSNs and its 
biochemical characteristics owing to its coupling to non-canonical Gq-mediated signaling. 
Together, our findings may open a new conceptual framework to understand the role of 
coordinated adenosine-cannabinoid function in the indirect striatal pathway, which may be 
relevant in motor function and neural diseases. 
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FIGURE LEGENDS 
 
Figure 1. A2AR-CB1R heteromers are located on GABAergic neurons rather than 
glutamatergic projections in the mouse dorsal striatum. (a, b) PLA assays were performed 
in dorsal-striatum sections from 3-4 month-old mice of different genotypes. A2AR-CB1R 
heteromers are shown as green dots. Nuclei are colored in blue by DAPI staining. (a) 
Representative low-magnification image of tissue sections used for PLA assays. Left, DAPI-
stained field; right, bright field. Scale bar: 1 mm. Representative pictures from control CB1R-
floxed, GABA-CB1R-/-, Glu-CB1R-/- and GABA-Glu-CB1R-/- mice. Scale bar: 20 μm. (b) 
Representative pictures from Stop-CB1R, GABA-CB1R-RS mice, Glu-CB1R-RS mice and 
CB1R-RS mice. Scale bar: 20 μm. (c) Quantification of the number of cells containing one or 
more dots expressed as the percentage of the total number of cells (blue nuclei). Data are the 
mean ± SEM of counts in 5-14 different fields from 3 different animals of each type. One-way 
ANOVA followed by Dunnet post hoc test showed a significant (*p < 0.05, ***p < 0.001) 
decrease of heteromer expression compared to control CB1R-floxed mice (a) or to CB1R-RS 
mice (b). Further details of statistical analyses are given in Supplementary Table S2. 
 
Figure 2. A2AR-CB1R heteromers expressed in the mouse dorsal striatum are functional. 
(a, c) ERK and Akt phosphorylation was determined in striatal slices from 3-4 month-old 
C57BL/6N mice pre-treated for 4 h with medium (a) or with 4 μM TM5, TM6 or TM7 
peptides alone or in combination (c). Slices were then preincubated for 20 min with vehicle, 
the CB1R antagonist SR141716 (10 μM) or the A2AR antagonist ZM241385 (10 μM) before 
the addition of vehicle, the CB1R agonist WIN-55,212-2 (1 μM), the A2AR agonist CGS21680 
(1 μM) or both, for 10 min. Immunoreactive bands from 3-6 slices from 12 different animals 
were quantified for each condition. Values represent mean ± SEM of percentage of 
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phosphorylation relative to basal levels found in vehicle only-treated slices (100%, dotted 
line). One-way ANOVA showed a significant (*p < 0.05, **p < 0.01, ***p < 0.001) effect 
over basal, or of agonist plus antagonist treatment over agonist-only treatment (#p < 0.05, ##p 
< 0.01, ###p < 0.001). Further details of statistical analyses are given in Supplementary Table 
S2. In (a), representative Western blots are shown at the top of each panel. (b) Schematic 
representation of the bimolecular fluorescence complementation technique showing that 
fluorescence only appears after the YFP Venus hemiprotein (cYFP or nYFP) 
complementation due to the proximity of the two receptors fused to hemi-YFP Venus proteins 
(top panel). In the bottom panel, fluorescence at 530 nm was monitored in HEK-293T cells 
transfected with the indicated amounts of cDNA encoding CB1R-nYFP and A2AR-cYFP 
(equal amount for each construct) or, as a negative control, transfected with cDNA encoding 
CB1R-nYFP and the non-interacting D1R-cYFP. Transfected cells were treated for 4 h with 
medium or with 4 µM TM5, TM6 and/or TM7 peptides before fluorescence reading. Values 
represent mean ± SEM of percentage of fluorescence relative to A2AR-cYFP/CB1R-nYFP 
maximal complementation (n = 4-12 replicates from 3 independent experiments for each 
condition). One-way ANOVA showed a significant change in fluorescence over non-
transfected cells (**p < 0.01, ***p < 0.001), or of the peptide-treated over the corresponding 
non-peptide treated cells (###p < 0.001). Further details of statistical analyses are given in 
Supplementary Table S2. 
 
Figure 3. A2AR-CB1R heteromers expressed in wild-type STHdhQ7 and mutant 
huntingtin-expressing STHdhQ111 striatal neuroblasts signal via Gq protein rather than 
Gi or Gs protein. (a) PLA assays were performed in STHdhQ7 and STHdhQ111 cells. A2AR-
CB1R heteromers are shown as green dots. Nuclei are colored in blue by DAPI staining. 
Controls in the absence of anti-A2AR primary antibody were also performed. Representative 
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pictures are shown. Scale bar: 20 μm. (b) Dynamic mass redistribution (DMR) assays were 
performed in STHdhQ7 and STHdhQ111 cells pretreated overnight with vehicle, pertussis toxin 
(PTX; 10 ng/ml) or cholera toxin (CTX; 100 ng/ml), and further treated with vehicle, the 
A2AR agonist CGS21680 (1 μM) or the CB1R agonist CP-55,940 (1 μM). (c) DMR assays in 
STHdhQ7 and STHdhQ111 cells preincubated for 30 min with vehicle or the Gq protein inhibitor 
YM-254890 (1 μM), and then activated with the A2AR agonist CGS21680 (1 μM) or the 
CB1R agonist CP-55,940 (1 μM). (d) DMR assays showing negative cross-talk (top panels) 
and cross-antagonism (bottom panels) between A2AR and CB1R signaling. STHdhQ7 and 
STHdhQ111 cells were not pre-treated (top panels) or pre-treated for 4 h with medium (left 
bottom panels) or with 4 µM TM5 plus TM6 (right bottom panels) before incubation for 30 
min with vehicle, the CB1R antagonist SR141716 (RIM; 1 μM) or the A2AR antagonist 
ZM241385 (1 μM), and then activated with vehicle, CGS21680 (1 μM) or CP-55,940 (1 μM). 
In (b-d) the resulting shifts of reflected light wavelength (pm) were monitored over time. 
Each panel is a representative experiment of n = 3 different experiments. Each curve is the 
mean of a representative optical trace experiment carried out in triplicates. 
 
Figure 4. Functional A2AR-CB1R heteromers are expressed in HdhQ7/Q111 HD mice at 
early but not advanced disease stages. (a) PLA assays were performed in dorsal-striatum 
sections from wild-type HdhQ7/Q7 mice and mutant huntingtin-expressing knock-in HdhQ7/Q111 
mice. A2AR-CB1R heteromers are shown as green dots in mice at 4, 6 and 8 months of age. 
Nuclei are colored in blue by DAPI staining. Representative pictures are shown. Scale bar: 20 
μm. Quantification of the number of cells containing one or more dots expressed as the 
percentage of the total number of cells (blue nuclei). Data are the mean ± SEM of counts in 
11-26 different fields from 5 different animals of each type. One-way ANOVA followed by 
Bonferroni post hoc test showed showed a significant (***p < 0.001) decrease of heteromer 
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expression in HdhQ7/Q111compared to the respective age-matched HdhQ7/Q7 mice. (b-e) ERK 
phosphorylation (b, d) and Akt phosphorylation (c, e) were determined in striatal slices from 6 
month-old wild-type HdhQ7/Q7 mice (b, c) and mutant huntingtin-expressing knock-in 
HdhQ7/Q111 mice (d, e). Slices were preincubated for 20 min with vehicle, the CB1R antagonist 
SR141716 (RIM; 1 μM) or the A2AR antagonist ZM241385 (1 μM) before the addition of 
vehicle or the CB1R agonist WIN-55,212-2 (1 μM), the A2AR agonist CGS21680 (1 μM), or 
both, for 10 min. Immunoreactive bands from 4-6 slices of 5-6 different animals were 
quantified for each condition. Values represent mean ± SEM of percentage of phosphorylation 
relative to basal levels found in vehicle only-treated slices (100%, dotted line). Representative 
Western blots are shown at the top of each panel. One-way ANOVA showed a significant 
effect over basal (*p < 0.05, **p < 0.01, ***p < 0.001), or of the antagonist plus agonist 
treatment over the agonist-only treatment (#p < 0.05, ##p < 0.01, ###p < 0.001). Further details 
of statistical analyses are given in Supplementary Table S2. 
 
Figure 5. A2AR-CB1R heteromers are lost in the caudate-putamen of high-grade HD 
patients. PLA assays were performed in caudate-putamen sections of post-mortem samples 
from control subjects (a) and HD patients at different grades (b-f). A2AR-CB1R heteromers are 
shown as green dots. Nuclei are colored in blue by DAPI staining. Representative pictures are 
shown. Scale bar: 20 μm. (g) Quantification of the number of cells containing one or more 
dots expressed as the percentage of the total number of cells (blue nuclei). Data are the mean 
± SEM of counts in 21-43 different fields from 5 control subjects, 5 low-grade HD patients (1 
grade 0, 2 grade 1, plus 2 grade 2) and 5 high-grade HD patients (2 grade 3, plus 3 grade 4). 
The characteristics of these human samples are shown in Supplementary Table S1. One-way 
ANOVA followed by Dunnet post hoc test showed a significant (***p < 0.001) decrease of 
heteromer expression compared to control subjects. Further details of statistical analyses are 
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given in Supplementary Table S2. (h) Scheme depicting the proposed location and G protein-
coupling of the A2AR-CB1R heteromer in the dorsal striatum. It is currently believed (left) that 
the A2AR-CB1R heteromer is located on corticostriatal projections as well as on the 
somatodendritic compartment of indirect-pathway MSNs. Each protomer would maintain its 
canonical G protein coupling (Gs for A2AR, and Gi for CB1R). In this study we propose 
(middle) that the A2AR-CB1R heteromer is located mostly on indirect-pathway MSNs, not 
only on their somatodendritic compartment but also likely on their terminals. According to 
our data, the A2AR-CB1R heteromer would facilitate Gq rather than Gs or Gi coupling. In 
symptomatic HD (right), the A2AR-CB1R heteromer would be disrupted into its constituting 
protomers. 
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